Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

ClinicalTrials.gov ID: NCT00991276

Public ClinicalTrials.gov record NCT00991276. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography Study Of Pregabalin And Pramipexole In Adults With Restless Legs Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the efficacy and safety of pregabalin and pramipexole versus placebo in the treatment of restless legs syndrome and associated sleep disturbance.

Study identification

NCT ID
NCT00991276
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
85 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2009
Primary completion
May 31, 2011
Completion
May 31, 2011
Last update posted
Feb 14, 2021

2009 – 2011

United States locations

U.S. sites
41
U.S. states
20
U.S. cities
38
Facility City State ZIP Site status
Pfizer Investigational Site Jasper Alabama 35501
Pfizer Investigational Site Phoenix Arizona 85037
Pfizer Investigational Site Tucson Arizona 85712
Pfizer Investigational Site Little Rock Arkansas 72205
Pfizer Investigational Site Little Rock Arkansas 72211
Pfizer Investigational Site Burlingame California 94010
Pfizer Investigational Site Pasadena California 91106
Pfizer Investigational Site Redlands California 92373
Pfizer Investigational Site San Diego California 92103
Pfizer Investigational Site San Diego California 92121
Pfizer Investigational Site Santa Ana California 92705
Pfizer Investigational Site Santa Monica California 90404
Pfizer Investigational Site Aurora Colorado 80012
Pfizer Investigational Site Hallandale Florida 33009
Pfizer Investigational Site Miami Florida 33143
Pfizer Investigational Site Pembroke Pines Florida 33026
Pfizer Investigational Site Spring Hill Florida 34609
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Macon Georgia 31201
Pfizer Investigational Site Overland Park Kansas 66212
Pfizer Investigational Site Crestview Hills Kentucky 41017
Pfizer Investigational Site Lexington Kentucky 40513
Pfizer Investigational Site Baton Rouge Louisiana 70809
Pfizer Investigational Site Chevy Chase Maryland 20815
Pfizer Investigational Site Brighton Massachusetts 02135
Pfizer Investigational Site Kalamazoo Michigan 49048
Pfizer Investigational Site Portage Michigan 49024
Pfizer Investigational Site New York New York 10019
Pfizer Investigational Site Hickory North Carolina 28601
Pfizer Investigational Site Raleigh North Carolina 27607
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Cincinnati Ohio 45227
Pfizer Investigational Site Dublin Ohio 43017
Pfizer Investigational Site Middleburg Heights Ohio 44130
Pfizer Investigational Site Oklahoma City Oklahoma 73112
Pfizer Investigational Site Clarks Summit Pennsylvania 18411
Pfizer Investigational Site Lafayette Hill Pennsylvania 19444
Pfizer Investigational Site Columbia South Carolina 29201
Pfizer Investigational Site Austin Texas 78731
Pfizer Investigational Site Austin Texas 78756
Pfizer Investigational Site Dallas Texas 75231

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00991276, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 14, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00991276 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →